Laurus Labs Limited

Corporate Office
2"d Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 50003~. Telangana, India
T +91 ~ 0 66 59 ~333, 3980 ~333, 23~2 0500 I 501
LAURUS Labs
F +91 ~0 66 59 ~320 I 3980 ~320 Knowledge . Innovation . Excellence

April29, 2021

To To

The Corporate Relations Department The Listing Department

BSE Limited National Stock Exchange of India Limited
Phiroz Jeejeebhoy Towers, 25th Floor, Exchange Plaza,
Dalal Street Bandra Kurla Complex, Bandra (East)
Mumbai - 400001 Mumbai - 400 051

Code: 540222 Code: LAURUSLABS

Dear Sirs,

Sub: Investors/Analysts Presentation

Please find enclosed the presentation to the Investors/Analysts on the Standalone and
Consolidated Financial Results of the Company for the Quarter and year ended March 31,
2021, for the Investors/Analysts call scheduled on April 30, 2021, which was already
intimated on April 26, 2021.

The presentation is also being uploaded on the website of the Company www.lauruslabs.com.

Please take the information on record.

/

Thanking you,

Yours sincerely,
For Laurus Labs Limited

· ~~
G. Venkateswar'Redd~____,
Company Secretary

Encl: As above

Registered Office : Plot No:21 , Jawaharlal Nehru Ph arm a City, Parawada, Visakhapatnam - 53102 1, Andhra Pradesh, India. CI N : L2~239AP2005PLCO~ 7518
T +91 891 660 1222, 306 1222, F +91 891 660 1270, 306 1270, E info@lauruslabs.com W lauruslabs.com

LAURUS Generics LAURUS Generics LAURUS Synthesis LAURUS Ingredients

Active Pharmaceutical Ingredients & Intermediates Finished Dosage Forms Contract Development & Manufacturing Services Specialty Ingredients lor Nutraceutical & Allied Industry
LAURUS LABS LIMITED
Q4 & FY21
INVESTOR PRESENTATION
April 29, 2021

BSE: 540222
NSE : LAURUSLABS
Disclaimer
This presentation contains statements that constitute “forward looking statements” including and without
limitation, statements relating to the implementation of strategic initiatives, and other statements relating to
our future business developments and economic performance. While these forward looking statements
represent our judgment and future expectations concerning the development of our business, such statements
reflect various assumptions concerning future developments and a number of risks, uncertainties and other
important factors that could cause actual developments and results to differ materially from our expectations.
These factors include, but are not limited to, general market, macro-economic, governmental and regulatory
trends, movements in currency exchange and interest rates, competitive pressures, technological
developments, changes in the financial conditions of third parties dealing with us, regulatory and legislative
developments which could adversely affect our business and financial performance.

Laurus Labs undertakes no obligation to publicly revise any forward looking statements to reflect future events
or circumstances.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from
Laurus Labs Limited.

2
 ₹ Cr
Consistent Quarterly Performance
Revenue (YoY Gr 70 %) EBITDA (YoY Gr 176%) MARGIN %
33% 34% 34%
1,412 29%
1,289
1,139
23%
20% 21%
974
839 16%
712 730 477
433
551 379
284
193
140 150
87

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
FY20 FY20 FY20 FY20 FY21 FY21 FY21 FY21 FY20 FY20 FY20 FY20 FY21 FY21 FY21 FY21

21% 21% 21%

350

PAT (YoY Gr 286%) 21% EPS ₹ (face value ₹ 2/- per share)
300 Margin % 18%
(YoY Gr 281%)*
297 5.5
250

273 16% 5.1

13% 4.5
200
242
10% 11%

150

8% 172 3.2

2.1
100

110 6%

50
3% 73 1.1 1.4
57
0 15 1%
0.2

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
FY20 FY20 FY20 FY20 FY21 FY21 FY21 FY21 FY20 FY20 FY20 FY20 FY21 FY21 FY21 FY21
* The equity shares of the Company of ₹ 10/- each sub-divided into 5 equity shares of ₹ 2/- each w.e.f. September 30, 2020, accordingly EPS has been restated. 3
YOY Gr : FY 21 full year vs FY 20 full year
 Business Snapshot
Division Generic API • Generic FDF • Synthesis (CDMO) • Bio

Overview • Development, manufacture and sale of • Developing and manufacturing oral solid • Contract development and manufacturing • Bio - Manufacturing
APIs and Advanced Intermediates formulations for LMIC, North America & EU services for global pharmaceutical Company
• Leadership in various High Value and Markets. companies and several late stage projects • Recombinant products -
High Volume APIs with sizeable Global • Backed by in house API strengths executed animal origin free
Market share. • Steroids and Hormone manufacturing products for safer, viral
• High potent manufacturing units. capability free bio manufacturing
• Precision Fermentation
capabilities - scale up
expertise and large scale
manufacturing
capabilities

Products and • Anti – Viral • Anti – Viral • Commercial scale contract manufacturing • Access to Bio based
Service Offerings technical expertise (used
• Anti-diabetic • Anti-diabetic • Clinical phase supplies
in Vaccine, insulin,
• CVS • CVS • Analytical and research services biologic, manufacturing
• PPIs • PPIs • Nutraceuticals, dietary supplements and • Enzymes bio-catalysis
cosmeceutical products (Green API process)
• Oncology • CNS
• Large Fermentation
capability

Filings • Commercialized 60+ products • Filed 27 ANDAs with USFDA and 9 Final • API validation planned in Unit 05
approvals and 8 tentative approvals In • Custom development of ophthalmic portfolio
• 61 DMFs filed
addition completed 2 products validation initiated
• Field 12 dossiers in Canada, 9 in Europe, 8
• LSPL – API validations planned
with WHO, 2 in South Africa, 2 in India & 14
products filed in various ROW markets.

Infrastructure • 4 Manufacturing facilities, (4,186 KL) (1) • 5 bn Units / year capacity • Dedicated manufacturing (Unit – 5) Capacity • 2 manufacturing
(2) • Capacity enhancement under progress (137 KL) for steroidal and hormonal facilities. The first one
• ~1,000 KL under expansion intermediates has fermentation
• Set up a dedicated block in Unit 4 for high capacity of 10,750 Lts
potent phytochemicals APIs while the second facility
• Incorporated Laurus Synthesis Capacity (149 has 180,000 Lts
KL)

(1) Includes ingredients products excluding Unit 2 API & Kilo lab (2) APIs , Ingredients and Synthesis (other than Aspen supplies) are 4
capacity manufactured at Unit 1,3 ,4 & 6
 Segmental Revenue Breakup ₹ Cr

Generics API Generics FDF Synthesis

452 430 430 176

797 148
731 352
127
571 267 116
522 100
424

Q4 Q1 Q2 Q3 Q4 Q4 Q1 Q2 Q3 Q4 Q4 Q1 Q2 Q3 Q4
FY20 FY21 FY21 FY21 FY21 FY20 FY21 FY21 FY21 FY21 FY20 FY21 FY21 FY21 FY21

• Generic API division showcased a robust growth of 61% YoY Q4 FY 21 Contribution

• Anti Viral segment recorded a robust growth of 70% YoY 1%

• Generic FDF Revenue Showcased a healthy growth of 102% YoY 30% Generics API
• The growth was led by higher LMIC Market volumes and increased
volumes from North America and EU Synthesis
57%
• Commenced marketing of in-licensed products in the USA to Generics FDF
12%
leverage front-end capabilities
Bio
• Custom Synthesis division recorded a strong growth of 35% YoY

5
 Generic API Division ₹ Cr

Anti Viral API Onco API Other API

568 569
166
86
135
379 64 62
336 59 106
99
51 92
273

Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21

 Strong demand in 1st line ARV API

 Order book position is robust
Q4 FY 21 Contribution
 Adding more capacity to meet the growing demand
 Other API segment (incl. CVS and Diabetes) reported good growth
21%
 Under discussion with Key Generic Partners for CM opportunity
 Creating dedicated block for Non-ARV APIs including expansion for Anti Viral
8%
High Potent capacity at Unit 4 Onco
71%
Others

6
Generic FDF Division ₹ Cr

452
430 430

352

267

Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21

 FDF Business delivered robust growth for the quarter. This is driven by continued strong demand
in ARV segment of LMIC region and portfolio expansion in developed markets
 Overall FDF revenue for FY 21 grew by 102% YoY
 Strong order book in all geographies
 2 Additional products validated as part of our CDMO expansion in EU
 FDF capacity debottlenecking completed
 New manufacturing block will be commercialized by Sep 2021

7
Synthesis (CDMO) Division ₹ Cr

176
148
127
116
100

Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21

 Synthesis business delivered robust growth for the quarter

 Total Number of Active Projects in the CDMO division stood at the end of FY21 was 50 (vs 40 in
FY20)
 Multiple Partnership proposals are in collaborative phase.
 Created a 100% subsidiary for Synthesis business and acquired small facility at Vizag under
this. Also, creating a dedicated R&D center for the Synthesis Division

8
 15 years journey so far

As on As on As on
Capabilities * Mar-11 Mar-16 Mar-21 Financials (₹ Cr) *
(for each period of 5 Yrs) FY 06-FY 11 FY 11-FY 16 FY 16-FY 21
Sources

Description of the ARV API API Pharmaceutical

Company company Company Company
Cash Profit (PAT +Dep) 7 633 2,478

Team Strength 883 2,266 4,808

8 Equity incl. Sec. Premium 127 359 313

Manufacturing units 1 2

Reactor Volume (KL) 220 1,870 4,638 Net Debt 230 773 390

Formulation OSD (bn) - 2 5 Total - Sources 365 1,765 2,991

DMF’s 12 28 61 Application
ANDA’s - Total filed
27 Gross block addition 241 1,187 1,984
- Para IV
- - 2
- First to File
7 NWC addition 123 572 856
Patents - Filed 48 218 292
- Granted - 25 150 Dividend 0 6 151

US FDA approved
1 2 5 Total - Application 365 1,765 2,991
manufacturing sites

* Consolidated numbers

9
5 year Division wise Revenue Contribution

2%
7% 9% 10%
3% 13%
8% 8% 8% 29%
35%
6% 9%
8%

10%

14%
11%

11%
11%

82% 7%
5%
77% 74%
66%

39% 38%

FY 16 FY 17 FY 18 FY 19 FY 20 FY 21

Anti Viral API Onco API Other API Custom Synthesis Generic FDF

10
Financial Track Record – Trend from FY17 to FY21 ₹ Cr

Revenue EBITDA MARGIN % 33% PAT EPS in ₹

18.3

4,814 23%
21% 20%
16%
1,573
2,832 984
2,292
1,905 2,056 4.2 4.8
3.2
570 1.8
440 442 371
190 255
168
94
FY 17 FY 18 FY 19 FY 20 FY 21 FY 17 FY 18 FY 19 FY 20 FY 21 FY 17 FY 18 FY 19 FY 20 FY 21

Capex Spent % on Revenue Asset Turnover Dividend ₹ Cr Payout %

19%
15% 14% 1.41
11.2%
11%
1.03 9.2% 16.8% 10.0%
8% 1.03 7.9%
0.90 0.89
689 107

391
277 254 222
27
16 16 16

FY 17 FY 18 FY 19 FY 20 FY 21 FY 17 FY 18 FY 19 FY 20 FY 21
FY 17 FY 18 FY 19 FY 20 FY 21
 5 years Return Ratios
Pre Tax Return on Capital Return on Equity(2) (%) Net Debt/EBIDTA (3) (x)
Employed(1) (%)
45.1%
40.1%
2.8x

2.2x
1.9x 1.9x

16.5% 17.4%
13.7% 14.1% 15.3%
11.9%
8.2% 0.9x
6.2%

FY17 FY 18 FY 19 FY 20 FY 21 FY17 FY 18 FY 19 FY 20 FY 21 FY17 FY 18 FY 19 FY 20 FY 21

Note: Based on consolidated financials as per Ind AS

(1) Pre-tax RoCE is calculated as EBIT/Average Capital Net Debt ₹ Cr FY 17 FY 18 FY 19 FY 20 FY 21
Employed. Capital employed is defined as Net Worth + Long
Term and Short Term Borrowings + Current Portion of Long Long-Term 198 221 352 266 567
Term Borrowing - Cash Short-Term 644 759 684 791 886
(2) RoE is calculated as PAT/Average Net Worth Gross Debt 842 980 1,036 1,057 1,453
Less: Cash & Bank balances (2) (3) (3) (2) (48)
(3) Net Debt means total debt less cash balance Net Debt 840 977 1,033 1,055 1,405

12
Manufacturing Facilities at Parawada, Vizag

Unit-I • Located at Jawaharlal Nehru Pharma City, Visakhapatnam, India.

• API manufacturing facility and includes capacity for ingredients, synthesis and contract
manufacturing.
• Commenced operations in 2007.
• 328 reactors with 1,226 Kilo Liters capacity.
• Received approvals from US FDA, WHO-Geneva, NIP – Hungary, KFDA, COFEPRIS, PMDA,
ANVISA & JAZMP – Slovenia.

Unit-III • Located at Jawaharlal Nehru Pharma City, Visakhapatnam, India.

• API manufacturing facility and includes capacity for ingredients, synthesis and contract
manufacturing.
• Commenced operations in 2015.
• 259 reactors with 1,982 Kilo Litres capacity.
• Received approvals from USFDA, WHO – Geneva, NIP – Hungary, COFEPRIS, KFDA, ANVISA
& JAZMP – Slovenia.

Unit-V • Located at Jawaharlal Nehru Pharma City, Visakhapatnam, India. (SEZ)

• A dedicated Hormone and Steroid facility for Aspen
• Commenced operations in 2017.
• 46 reactors with 137 Kilo Litres capacity .

13
Manufacturing Facilities at Atchutapuram, Vizag
• Located at APIIC, Atchutapuram, Visakhapatnam, India. (SEZ)
Unit-II • FDF and API manufacturing facility
• Commenced operations in 2017.
• FDF - capacity of 5 bn tablets/capsules per year. Capacity expansion initiated and will be
operational by Q1 FY22
• API block with 12 reactors with 83 Kilo Liters capacity.
• Received approvals from BVG Hamburg Germany, USFDA, WHO – Geneva, JAZMP –
Slovenia, ANVISA and various African Countries

Unit-IV • Located at APIIC, Atchutapuram, Visakhapatnam, India.

• API manufacturing facility and includes capacity for Ingredients, Synthesis and
Contract Manufacturing.
• Commercial operations in 2018
• 54 reactors with 221 Kilo Liters capacity
• Received approval from WHO, USFDA and COFEPRIS – Mexico

Unit-VI • Located at APIIC, Atchutapuram, Visakhapatnam, India.

• API manufacturing facility.
• Commercial operations in 2018

• 68 reactors with 758 Kilo Liters capacity.

• Received approval from USFDA

14
 Quality Focus & Regulatory Audits
No of USFDA
Facility Key Agencies Recent Inspection Year audit ( since
inception
Kilo Lab –
USFDA 2016 – EIR received 3
R&D

USFDA, WHO – Geneva, ANVISA,

2019 - 20 – EIR Received,
Unit 1 COFEPRIS – Mexico and JZAMP 5
and cGMP certification received
Slovenia

USFDA, WHO – Geneva, BGV Laurus’

Hamburg, ANVISA, JZAMP – 2019 - 20 – EIR Received, and Philosophy
Unit 2 3
Slovenia & Various African cGMP certification received
“One Quality
Countries
Standard for all
markets”
USFDA, WHO – Geneva, ANVISA,
2019 - 20 – EIR received, and
Unit 3 COFEPRIS – Mexico and JZAMP 5
cGMP certification received
Slovenia

WHO, USFDA & COFEPRIS – 2019- 20 – EIR received & cGMP

Unit 4 1
Mexico certification received

Unit 5 No DMFs Filed

Unit 6 USFDA 2019 – EIR received 1 15

 Strong R&D Capabilities

R&D Centre - Hyd 184

166 160
134
114
85 7.4%
7.1% 5.6% 5.7%
4.8%
3.8%

FY16 FY17 FY18 FY 19 FY 20 FY 21

R&D Spent ₹ Cr % of Revenue

Current Filings Status

Therapy US ANDA Europe Canada Patents Patents
ARV 16 4 5 DMFs Filed Granted

Anti- Diabetic 3 3 3 Cumulative

CVS 3 - 1 Filings 61 292 150

CNS 1 1 1
 Invest in portfolio based on complexity and scale
Others 4 1 4  Creating separate R&D center for Synthesis
Division
Total 27 9 14
 Filing pace to increase in FY 22 across markets

16
Covid-19 Response
Combatting without Compromising on strategic priorities

 Focused execution on managing manufacturing, supply chain to ensue adequate stock of materials,
Business timely supplies and future capacity enhancements (How)
Continuity
 Set up a dedicated team to ensure real-time assessment of liquidity position & eliminate inefficiencies

 Stepped up Executive council to ensure safety of employees and their family by taking precautionary
Employee measures; social distancing, sanitization drive across plants and offices
Safety  Additional Buses provided to maintain physical distance
 Creation of company-wide Covid-19 online resource center

 Donated to support patients, healthcare ecosystem and Communities including PM care Fund or CM
Community Relief Fund
Reach
 Serving food, sanitization support to the needy and poor families

17
 Outlook for FY22 & Beyond
Healthy Revenue visibility on the
back of robust Order Book
• Partnership with Global Fund offers higher
volume contracts with reasonable
predictability in FDF Tender business.
• Have a healthy order book for FY 22 &
beyond in FDF CMO business with a
strategic partner in EU
• Robust growth in Other API segment to
continue on the back of higher order book
visibility from key therapeutic segments
like CVS, Anti Diabetic and PPIs
• Several new customers added with
programs in various clinical phases
• Incorporated a Wholly Owned subsidiary to
give increased focus and eventually
dedicated R&D and Manufacturing for
Synthesis Business
• Other therapeutic areas and Oncology to
offer consistent opportunities to broaden
scope, with ongoing new product
introduction
Changing business mix to drive
growth
• Generic FDF segment contributed ~35%
in FY 21 to total revenue as against just
2% in FY19
• Non ARV API business to contribute
significantly showcasing the speed of
diversification of revenues.
• The change in revenue & product mix
to generate better profitability &
margins
• Synthesis business to show gains in line
with new customer additions in CDMO
• Acquired Aspen’s South African
Subsidiary, in order to get a foothold in
worlds' largest Generic Accessible ARV
market
• The Richcore (renamed as Laurus Bio)
acquisition will help us enter into high
growth segments of AOF products,
Enzymes and Biologics
Capacity augmentation to result
in better return ratios
• Among top 5 in India in terms of
Reactor capacities
• All the green field expansion have
turned Cash positive in FY20 with near
maximum utilization
• Continue to undertake Brown Field
Capex programs for Capacity addition in
line with strong order book visibility
and business outlook
• Brown Field capex in existing sites to
have shorter payback period and ROCE
accretive
• Doubling our FDF capacity by FY22
• Acquired assets of an API Unit in Vizag
to be used for backward integration and
pre-clinical chemistry
• Initiating green field expansion for all
the divisions (API, FDF and Synthesis)
18
Key Milestones

• Crossed INR 40 billion of revenue

• Incorporated Laurus Synthesis Pvt. Ltd & acquired assets of an API Unit in Vizag
• Acquired Aspen’s South Africa Subsidiary – Laurus Generics SA(PTY) Limited
• Laurus Synthesis Inc USA is merged with Laurus Generics Inc USA.
• INR 10 billion FDF Sales

• Crossed INR 20 billion of revenue

• Commenced commercial operations from Unit 4 • Incorporated Laurus Ingredients
• Incorporated a subsidiary in Germany Pvt. Ltd. A Wholly Owned step
• Commenced FDF supplies. down subsidiary of Laurus
Synthesis Pvt. Ltd.
• Acquisition of 79.21% stake in
Richcore Life Sciences Pvt Ltd
• Successfully listed on BSE &NSE
(Laurus Bio)
• Filed first ANDA for US market
• Acquired 100% stake in Sriam Labs Pvt Ltd. • Entered into Strategic partnership
with Global Fund for 3.5 years.

• Investment of INR 300 Cr by Warburg Pincus

• Incorporated First Subsidiary in USA.
• Forged partnership with ASPEN for CRAMS • Commenced commercial operations at Unit 2
• Commenced commercial supplies from Unit 5 for Aspen
• Incorporated subsidiaries in UK & USA

• Investment of INR 60 Cr by
FIL Capital Management and • Commenced commercial operations at Unit 3.
Promoters

• Set up the R&D Centre at • Crossed INR 10 billion of revenues

IKP, Knowledge Park,
Hyderabad

• Commenced commercial operations at Unit 1

19
Board of Directors & Leadership Team
Name
Dr Satyanarayana Chava
Ravi Kumar V V
Dr Lakshmana Rao C V
Name
Dr. M. Venu Gopala Rao
Chandrakanth Chereddi
Aruna Rajendra Bhinge
Dr. Rajesh Koshy Chandy
Dr. Ravindranath Kancherla
Dr. Satyanarayana Chava Mr V.V Ravi Kumar
Founder & CEO
Executive Directors
Background
 Whole-time Director, Founder and Chief Executive Officer
 Whole-time Director and CFO
 Whole-time Director and Head, Quality
Non-Executive Directors
Background
 Non Executive Chairman and Independent Director
 Non-Executive Director, Former Head of Generic FDF and Strategy at Laurus Labs Limited
 Independent Director; Former Head of Food Security Agenda, APAC at Syngenta India Limited
 Independent Director; Professor of Marketing at the London Business School
 Independent Director and Founder-Member and Treasurer of ELSA of Asia in Singapore and Chairman of
Global Hospitals
Dr. Lakshmana Rao C V Dr. V Uma Maheswer Rao Mr. S. Srinivasa Rao
ED & CFO ED & Head, Quality Exec. VP & Head, API & R&D Exec. VP – Operations
Mr. Krishna Chaitanya Chava G. Venkateshwar Reddy
Head – Synthesis Division CS & AVP – Legal &
Secretarial
20
Ownership Structure
Corporate Structure
Laurus Labs Limited All are 100%
Subsidiaries except
India Laurus Bio*

Sriam Laurus *Laurus

Laurus Laurus
Labs Pvt Ltd. Holdings Ltd. Bio Pvt Ltd.
Synthesis Pvt. Ltd Generics SA (PTY) Ltd
India UK 79.21%

Laurus Laurus
Laurus
Generics Inc. Generics GmbH.
Ingredients Pvt. Ltd.
USA Germany

Shareholding pattern *

27.45% 2.05% 20.68% 1.11% 48.71%

Promoter Non-
Foreign QIBs Institutions
and Mutual
Portfolio (Individuals +
Promoter Funds
Investors Others)
Group

* As of 31st March 2021

21
Conference Call Details
Results conference call on Friday April 30, 2021 at 11:00 AM IST

Details of the conference call are as follows

Location Dial-In Details

Conference dial-in Universal Dial-In +91 22 6280 1148

India Local access Number +91 22 7115 8049 Available all over India

Singapore 800 101 2045

Hong Kong 800 964 448

USA 1 866 746 2133

UK 0 808 101 1573

For Diamond pass please Copy this URL in your browser:

https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=7598724&linkSecurityString=1972ca58c0

22
Contact us
About Laurus Labs Ltd.
Laurus Labs is a leading research driven Pharmaceutical manufacturing Company in India. We have
grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology,
Cardiovascular, Anti-Diabetics, Anti-Asthma and Gastroenterology .We are thriving on growth
opportunities in formulation manufacturing to service all leading markets of North America,
Europe and Low Middle Income Countries (LMIC). We are driving growth opportunities in Contract
Development and Manufacturing through our Synthesis business. Most of our manufacturing
facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA etc. Our
approach remains to identify and invest ahead of time with strategic investments in State-of-the-
Art R&D and Manufacturing Infrastructure enabling us to become a quality supplier of high
volume products. Corporate Identification No: L24239AP2005PLC047518.

Laurus Labs is certified as “Great

Laurus Labs continues to be in Place to Work” for the third
the Fortune 500 Companies consecutive year 2020
List in India since 2017

For more information about us, please visit www.lauruslabs.com or contact:

Vivek Kumar
Tel: +91 040 6659 4366
Email: investorrelations@lauruslabs.com

23
Thank You